Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston Scientific loses appeal in J&J case

This article was originally published in The Gray Sheet

Executive Summary

Court of Appeals for the Federal Circuit in Washington, D.C., finds Boston Scientific's "Ding" patent for a drug-eluting stent coating system to be invalid as obvious over prior art. The ruling overturns a 2005 jury verdict in the U.S. District Court of Delaware that found the patent was valid and infringed by Johnson & Johnson/Cordis' Cypher sirolimus-eluting stent (1"The Gray Sheet" June 19, 2006, In Brief). Boston says it is considering options for challenging the decision

You may also be interested in...



Boston Scientific stent patent prevails

U.S. District Court for Delaware June 15 upholds a 2005 jury determination that Johnson & Johnson/Cordis' Cypher sirolimus-eluting stent infringes Boston Scientific's "Ding" patent for non-thrombogenic polymer technology. Cordis had asked the court to overturn the 2005 jury verdict and now says it will appeal the decision by District Court Judge Sue Robinson (1"The Gray Sheet" July 4, 2005, p. 5). The ruling is Robinson's third in six weeks on patent disputes between the sparring drug-eluting stent manufacturers. Prudential Equity Group senior medical device analyst Larry Biegelsen said in a June 15 research note that the continuing stent intellectual property battle between the two firms is "unlikely to have a substantial financial impact on either party"...

Novartis Q4 Preview: Launches Likely To Deliver

Having had a very fruitful year in terms of regulatory approvals, the Swiss major will reveal how successful its new products have been commercially. Of particular interest will be the performance of eye drug Beovu as it takes on Bayer's rival Eylea.

Executives On The Move: New Picks For Finance Posts At Cambrex And Editas Medicine, And Zimmer Biomet Fills Communications Spot

Gene-editing company Editas Medicine appoints a new CFO, while Affimed and NexImmune bring new chief medical officers on board.

Topics

UsernamePublicRestriction

Register

MT027069

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel